Head and Neck Squamous Cell Carcinomas Market Forecast to 2036: Rising Demand, Regulatory Support, and New Product Launches Drive Expansion | Sidney Kimmel, Centre hospitalier de, Dana-Farber Cancer

The Key Head and Neck Squamous Cell Carcinomas Companies in the market include - M.D. Anderson Cancer Center, Sidney Kimmel, Centre hospitalier de, Dana-Farber Cancer Institute, Inovio Pharmaceuticals, Hansoh BioMedical R&D Company, Gilead Sciences, Merck Sharp & Dohme LLC, Exelixis, Sichuan Baili Pharmaceutical Co., Ltd., AVEO Pharmaceuticals, Inc., Benitec Biopharma, Inc., BeiGene, ALX Oncology Inc., Queensland Health, Regeneron Pharmaceuticals, and others.

(Albany, New York) - November 05, 2026: DelveInsight’s “Head and Neck Squamous Cell Carcinomas Market Insights, Epidemiology, and Market Forecast-2036″ report offers an in-depth understanding of the Head and Neck Squamous Cell Carcinomas, historical and forecasted epidemiology as well as the Head and Neck Squamous Cell Carcinomas market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

Get a Free sample for the Head and Neck Squamous Cell Carcinomas Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/head-and-neck-squamous-cell-carcinoma-market

 

Some of the key facts of the Head and Neck Squamous Cell Carcinomas Market Report:

• The Head and Neck Squamous Cell Carcinoma (HNSCC) market size was valued at approximately USD 850 million in 2025 and is forecast to reach nearly USD 2,560 million by 2036. The market is expected to expand at a CAGR of 10.5% during the 2026–2036 forecast period, driven by advancements in targeted therapies, immuno-oncology, and increasing treatment adoption.

• In October 2026, BNT113 plus pembrolizumab (BioNTech): The Phase II/III AHEAD-MERIT trial did not meet its first dual primary endpoint of progression-free survival compared with pembrolizumab alone in first-line HPV16-positive recurrent or metastatic HNSCC. The study will continue to assess overall survival, its second primary endpoint.

• In September 2026, Phase II HexAgon study results showed that INBRX-106, a hexavalent OX40 agonist, combined with pembrolizumab achieved a confirmed objective response rate of 48.3%, compared with 26.5% for pembrolizumab alone in first-line PD-L1-positive recurrent or metastatic HNSCC. The combination also demonstrated a six-month progression-free survival rate of 72.4% versus 42.8%.

• In August 2026, The Phase III VERSATILE-003 trial evaluating the HPV16-targeted immunotherapy PDS0101 in HNSCC was discontinued. The company indicated that it would prioritize other development activities and pursue a partnership strategy for PDS0101.

• In June 2026, CRB-701 (Corbus Pharmaceuticals): Updated Phase I/II clinical findings presented at the 2026 ASCO Annual Meeting demonstrated antitumor activity in patients with recurrent or metastatic HNSCC. Confirmed objective response rates were 33.3% in both the 2.7 mg/kg and 3.6 mg/kg dose groups, supporting further investigation of this Nectin-4-targeted ADC.

• In May 2026, JNJ-1900 (NBTXR3; Nanobiotix/Johnson & Johnson): The FDA accepted a protocol amendment to the ongoing Phase III NANORAY-312 study. The amendment removed the planned interim analysis and brought forward the final analysis by reducing the required number of events, potentially supporting an earlier assessment of the treatment in locally advanced HNSCC patients ineligible for platinum-based chemotherapy.

• In February 2026, The FDA has granted breakthrough therapy designation (BTD) to amivantamab and hyaluronidase-lpuj (RYBREVANT FASPRO; subcutaneous amivantamab) as monotherapy for the treatment of adult patients with recurrent or metastatic, HPV–unrelated HNSCC following disease progression on or after platinum-based chemotherapy and a PD-L1 or PD-1 inhibitor.

• In January 2026, BNT113 (BioNTech): The investigational HPV16-targeted mRNA cancer immunotherapy received FDA Fast Track Designation for evaluation in HPV16-positive recurrent or metastatic HNSCC. The candidate is being investigated in combination with pembrolizumab in the Phase II/III AHEAD-MERIT trial (NCT04534205).

• In August 2025, Merus announced that enrollment in the Phase III LiGeR-HN2 trial in HNSCC is expected to be completed by the end of 2025, and in May 2025, the company further announced that it anticipates sharing a topline interim readout in 2026 for Petosemtamab (MCLA-158).

• In August 2025, Health Canada has authorized pembrolizumab (Keytruda) for use as neoadjuvant therapy, followed by adjuvant therapy in combination with radiotherapy with or without cisplatin, and then as monotherapy, for adult patients with resectable, locally advanced head and neck squamous cell carcinoma (HNSCC) whose tumors show a PD-L1 combined positive score (CPS) of 1 or higher, as confirmed by a validated test.

• In February 2025, Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company focused on developing transformative bifunctional therapies for solid tumors, has announced the enrollment of the first patients in FORTIFI-HN01, a pivotal Phase 2/3 trial. This study evaluates ficerafusp alfa in combination with pembrolizumab as a first-line (1L) treatment for recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). Ficerafusp alfa is a first-in-class bifunctional antibody that integrates an epidermal growth factor receptor (EGFR)-targeting monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-β).

• In January 2025, Rakuten Medical administered the first dose in its intercontinental Phase III clinical trial evaluating ASP-1929, a photoimmunotherapy treatment for recurrent head and neck squamous cell carcinoma (HNSCC). This multi-center, randomized, open-label study will assess the efficacy of the company’s antibody-dye conjugate, which combines the antibody drug cetuximab with MSD’s leading monoclonal antibody, Keytruda (pembrolizumab).

• KEYTRUDA and OPDIVO are the primary PD-1 inhibitors approved for treating recurrent or metastatic (R/M) HNSCC.

• KEYTRUDA monotherapy is the preferred first-line treatment for recurrent or metastatic HNSCC with high PD-L1 expression. However, only about 20% of patients respond, and there is no significant difference based on HPV status. Currently, no treatments are specifically approved for HPV16+ cancers.

• According to DelveInsight’s estimates, the total incident cases of HNSCC in the 7MM were approximately 153,500 in 2025.

• It has been observed that among EU4 and the UK, site-specific cases of HNSCC were found maximum in the oral cavity in 2025.

• Germany accounted for about 2,700 Oropharyngeal squamous cell cancer (OPSCC) incident cases in 2025.

• Japan accounted for about 3,900 cases of HPV16+ OPSCC incident cases in 2025.

• Key Head and Neck Squamous Cell Carcinomas Companies: M.D. Anderson Cancer Center, Sidney Kimmel, Centre hospitalier de, Dana-Farber Cancer Institute, Inovio Pharmaceuticals, Hansoh BioMedical R&D Company, Gilead Sciences, Merck Sharp & Dohme LLC, Exelixis, Sichuan Baili Pharmaceutical Co., Ltd., AVEO Pharmaceuticals, Inc., Benitec Biopharma, Inc., BeiGene, ALX Oncology Inc., Queensland Health, Regeneron Pharmaceuticals, and others

• Key Head and Neck Squamous Cell Carcinomas Therapies: Pembrolizumab, Nivolumab, Durvalumab, Taxotere, CELLECTRA™-5P, HS-20093, Magrolimab, Lenvatinib, Zanzalintinib, BL-B01D1, Ficlatuzumab, BB-401, Tislelizumab, SI-B001, Evorpacept, Pembrolizumab, CMP-001, and others

• The Head and Neck Squamous Cell Carcinomas market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Head and Neck Squamous Cell Carcinomas pipeline products will significantly revolutionize the Head and Neck Squamous Cell Carcinomas market dynamics.

 

Head and Neck Squamous Cell Carcinomas Overview

Head and Neck Squamous Cell Carcinoma (HNSCC) refers to a group of cancers that originate in the squamous cells lining the mucous membranes of the head and neck region. This includes the oral cavity, throat (pharynx), and voice box (larynx), among other areas. Squamous cells are flat, thin cells that make up the epithelium, the outer layer of the skin and the lining of various organs.

 

To Know in detail about the Head and Neck Squamous Cell Carcinomas market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Head and Neck Squamous Cell Carcinomas Market Forecast

 

Head and Neck Squamous Cell Carcinomas Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the APAC countries from 2022-2036. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Head and Neck Squamous Cell Carcinomas Epidemiology Segmentation:

The Head and Neck Squamous Cell Carcinomas market report proffers epidemiological analysis for the study period 2022-2036 in the APAC region is segmented into:

• Total Prevalence of Head and Neck Squamous Cell Carcinomas

• Prevalent Cases of Head and Neck Squamous Cell Carcinomas by severity

• Gender-specific Prevalence of Head and Neck Squamous Cell Carcinomas

• Diagnosed Cases of Episodic and Chronic Head and Neck Squamous Cell Carcinomas

 

Download the report to understand which factors are driving Head and Neck Squamous Cell Carcinomas epidemiology trends @ Head and Neck Squamous Cell Carcinomas Epidemiology Forecast

 

Head and Neck Squamous Cell Carcinomas Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Head and Neck Squamous Cell Carcinomas market or expected to get launched during the study period. The analysis covers Head and Neck Squamous Cell Carcinomas market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Head and Neck Squamous Cell Carcinomas Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Head and Neck Squamous Cell Carcinomas Therapies and Key Companies

• (KEYTRUDA): Merck Sharp & Dohme

• Efti (eftilagimod alfa): Immutep/ Merck

• Pembrolizumab: M.D. Anderson Cancer Center

• Nivolumab: Sidney Kimmel

• Durvalumab: Centre hospitalier de

• Taxotere: Dana-Farber Cancer Institute

• CELLECTRA™-5P: Inovio Pharmaceuticals

• HS-20093: Hansoh BioMedical R&D Company

• Magrolimab: Gilead Sciences

• Lenvatinib: Merck Sharp & Dohme LLC

• Zanzalintinib: Exelixis

• BL-B01D1: Sichuan Baili Pharmaceutical Co., Ltd.

• Ficlatuzumab: AVEO Pharmaceuticals, Inc.

• BB-401: Benitec Biopharma, Inc.

• Tislelizumab: BeiGene

• SI-B001: Sichuan Baili Pharmaceutical Co., Ltd.

• Evorpacept: ALX Oncology Inc.

• Pembrolizumab: Queensland Health

• Evorpacept: ALX Oncology Inc.

• CMP-001: Regeneron Pharmaceuticals

 

Discover more about therapies set to grab major Head and Neck Squamous Cell Carcinomas market share @ Head and Neck Squamous Cell Carcinomas Treatment Landscape

 

Head and Neck Squamous Cell Carcinomas Market Drivers

• Rising incidence of tobacco use, alcohol consumption, and human papillomavirus (HPV)-associated cancers is significantly driving the prevalence of head and neck squamous cell carcinomas (HNSCC).

• Increasing awareness regarding early cancer diagnosis and growing adoption of advanced screening technologies are supporting timely treatment initiation.

• Advancements in immunotherapy, targeted therapy, and precision oncology are expanding treatment options and improving patient outcomes.

• Growing clinical trial activity focused on checkpoint inhibitors, monoclonal antibodies, and combination therapies is strengthening the HNSCC treatment pipeline.

 

Head and Neck Squamous Cell Carcinomas Market Barriers

• Late-stage diagnosis in many patients due to non-specific symptoms can limit treatment effectiveness and survival rates.

• High treatment costs associated with immunotherapies, biologics, and advanced radiation procedures may restrict accessibility in developing regions.

• Severe treatment-related side effects such as dysphagia, mucositis, and speech impairment may negatively impact patient quality of life and treatment adherence.

• Resistance to chemotherapy and immunotherapy in certain patient populations remains a major clinical challenge.

 

Scope of the Head and Neck Squamous Cell Carcinomas Market Report

• Study Period: 2022-2036

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Head and Neck Squamous Cell Carcinomas Companies: Pembrolizumab, Nivolumab, Durvalumab, Taxotere, CELLECTRA™-5P, HS-20093, Magrolimab, Lenvatinib, Zanzalintinib, BL-B01D1, Ficlatuzumab, BB-401, Tislelizumab, SI-B001, Evorpacept, Pembrolizumab, CMP-001, and others

• Key Head and Neck Squamous Cell Carcinomas Therapies: Pembrolizumab, Nivolumab, Durvalumab, Taxotere, CELLECTRA™-5P, HS-20093, Magrolimab, Lenvatinib, Zanzalintinib, BL-B01D1, Ficlatuzumab, BB-401, Tislelizumab, SI-B001, Evorpacept, Pembrolizumab, CMP-001, and others

• Head and Neck Squamous Cell Carcinomas Therapeutic Assessment: Head and Neck Squamous Cell Carcinomas current marketed and Head and Neck Squamous Cell Carcinomas emerging therapies

• Head and Neck Squamous Cell Carcinomas Market Dynamics: Head and Neck Squamous Cell Carcinomas market drivers and Head and Neck Squamous Cell Carcinomas market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Head and Neck Squamous Cell Carcinomas Unmet Needs, KOL’s views, Analyst’s views, Head and Neck Squamous Cell Carcinomas Market Access and Reimbursement

 

To know more about Head and Neck Squamous Cell Carcinomas companies working in the treatment market, visit @ Head and Neck Squamous Cell Carcinomas Clinical Trials and Therapeutic Assessment

 

Table of Contents

1. Head and Neck Squamous Cell Carcinomas Market Report Introduction

2. Executive Summary for Head and Neck Squamous Cell Carcinomas

3. SWOT analysis of Head and Neck Squamous Cell Carcinomas

4. Head and Neck Squamous Cell Carcinomas Patient Share (%) Overview at a Glance

5. Head and Neck Squamous Cell Carcinomas Market Overview at a Glance

6. Head and Neck Squamous Cell Carcinomas Disease Background and Overview

7. Head and Neck Squamous Cell Carcinomas Epidemiology and Patient Population

8. Country-Specific Patient Population of Head and Neck Squamous Cell Carcinomas

9. Head and Neck Squamous Cell Carcinomas Current Treatment and Medical Practices

10. Head and Neck Squamous Cell Carcinomas Unmet Needs

11. Head and Neck Squamous Cell Carcinomas Emerging Therapies

12. Head and Neck Squamous Cell Carcinomas Market Outlook

13. Country-Wise Head and Neck Squamous Cell Carcinomas Market Analysis (2022-2036)

14. Head and Neck Squamous Cell Carcinomas Market Access and Reimbursement of Therapies

15. Head and Neck Squamous Cell Carcinomas Market Drivers

16. Head and Neck Squamous Cell Carcinomas Market Barriers

17. Head and Neck Squamous Cell Carcinomas Appendix

18. Head and Neck Squamous Cell Carcinomas Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

A New Era of Luxury Lifestyle & Entertainment in South Asia

Grand Launch Celebration

Goa, India - November 5, 2026 -

About RKNS

RKNS is a next-generation luxury lifestyle and entertainment OTT platform designed to bring the world of entertainment together under one digital destination.

Our vision is to create a premium entertainment ecosystem for South Asia, connecting audiences through movies, web series, short films, original productions and exclusive digital entertainment in multiple regional and international languages.

RKNS is more than just an OTT platform. It is a destination for entertainment, creativity, culture and luxury lifestyle experiences.

We aim to bring diverse stories, talented creators, filmmakers and entertainment professionals together on one platform, making quality entertainment accessible to audiences across South Asia and beyond.

Our Vision

To become one of South Asia's leading multilingual entertainment and luxury lifestyle platforms, connecting millions of viewers through content without language barriers.

What Makes RKNS Special?

• Multilingual Entertainment: Content across multiple South Asian and international languages.
• Movies & Web Series: A diverse collection of entertainment for every audience.
• Short Films: A platform to showcase independent filmmakers and emerging talent.
• Original Productions: Exclusive entertainment and original digital content.
• Luxury Lifestyle: Bringing entertainment, premium experiences and lifestyle together.
• Global Audience: Connecting content creators and viewers beyond geographical boundaries.

Grand Launch Event – Goa 2026

We are delighted to announce the upcoming grand launch of RKNS OTT Platform in the beautiful destination of Goa, India.

Proposed Event Schedule:

• Duration: 4 Days & 3 Nights
• Location: Goa, India
• Tentative Dates: End of November or First Week of December 2026
• Special Attraction: Bollywood Night
• Grand OTT Platform Launch Celebration
• Entertainment, Networking & Luxury Hospitality
• Special Guests and Industry Networking

Join us for an unforgettable celebration as we introduce a new chapter in South Asian digital entertainment.

Our Mission

Our mission is to empower entertainment creators, support regional cinema, promote multilingual storytelling and deliver a premium digital entertainment experience to audiences worldwide.

RKNS – Entertainment Without Boundaries. Luxury Without Limits.

JOIN THE RKNS COMMUNITY

Telegram Community: https://t.me/rknstoken

WhatsApp Community: https://chat.whatsapp.com/Clrtty4u4UnEXAqJy5yj5E

Official Website: www.rknsevent.com

OTT Platform: https://rkns.tv

BE PART OF THE REVOLUTION

The future of entertainment is multilingual, digital and global.

Welcome to RKNS. Welcome to the Future of Entertainment!

Media Contact
Company Name: RKNS
Contact Person: Media Relations
Email:Send Email
Country: India
Website: https://rknsevent.com

Beyond the Criminal Justice Classroom Launches to Connect College Learning With Police Practice

New publication explores the observation, critical thinking, and writing skills students can practice before entering the field.

ATLANTA, GA - November 5, 2026 - Knowing the definition of evidence is one thing. Explaining why a particular piece of evidence matters is another. A new online publication, Beyond the Criminal Justice Classroom, explores that distinction through articles and fictional case exercises for criminal justice students, faculty, and police trainers.

Presented by the KLYVOREK Institute, the publication connects academic concepts with the questions, decisions, and documentation involved in police work. Its mission is reflected in its tagline: “Helping students think, write, and prepare for the realities of police work.”

Founder Edward Brown, a former metro Atlanta police sergeant and investigator with more than 30 years of law enforcement and public safety experience, developed the publication around a professional challenge he encountered: people who could explain an incident in conversation sometimes struggled to document it clearly.

The online journal shows students how to identify missing information, distinguish observations from assumptions, explain the relevance of evidence, and organize facts into clear narratives.

Initial articles include:

• The Case Made Sense Until the Student Had to Write It Down
• What Would Your Criminal Justice Students Ask If They Were First on the Scene?
• A Student Finds the Evidence. Can They Explain Why It Matters?
• Before Students Learn to Use AI for Police Reports, What Should They Learn to Do Themselves?

Readers can also explore KLYVOREK Institute’s fictional training scenarios, which offer opportunities to practice incident reports and warrant drafts using AI assistance. Participants remain responsible for reviewing their work and checking it against the scenario facts.

Criminal justice professors, academy instructors, and field training officers are invited to explore the publication, suggest topics, and discuss how scenario exercises might support their instruction.

About Beyond the Criminal Justice Classroom

Beyond the Criminal Justice Classroom is an educational online journal presented by the KLYVOREK Institute. It explores the connection between criminal justice education and practical police work through articles, fictional scenarios, and discussion of professional skills.

Media Contact
Company Name: From Class RoomTo Patrol
Contact Person: Edward Brown
Email:Send Email
Country: United States
Website: FromClassroomToPatrol.com

Stargardt Disease Clinical Trial Pipeline Gains Momentum: 20+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

The Stargardt Disease Clinical Trial analysis report delivers important insights into ongoing research on 20+ pipeline drugs, clinical strategies, upcoming therapeutics, and commercial analysis.

(Albany, US) On November 4, 2026, DelveInsight’s “Stargardt Disease Pipeline Insight 2025” report provides comprehensive insights about 20+ companies and 20+ pipeline drugs in the Stargardt Disease pipeline landscape. It covers the Stargardt Disease pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Curious about the latest updates in the Stargardt Disease Pipeline? @ https://www.delveinsight.com/sample-request/stargardt-disease-stgd-pipeline-insight

Key Takeaways from the Stargardt Disease Pipeline Report

• On October 29, 2026 – Alkeus Pharmaceuticals updated the regulatory status of Alkeus Pharmaceuticals' Phase III NORTHSTAR study evaluating gildeuretinol acetate (ALK-001) in Stargardt disease. The study was listed as authorized with recruitment pending across five European countries, representing further progress in the clinical development of this investigational oral therapy.
• On October 14, 2026 –Belite Bio announced the submission of marketing authorization applications for tinlarebant (LBS-008) through the Access Consortium pathway in Singapore, the United Kingdom, and Switzerland for the treatment of Stargardt Disease Type 1 (STGD1). These submissions complement the company's U.S. and Japanese regulatory applications and mark further progress toward potential global commercialization.
• On October 5, 2026 –AAVantgarde Bio presented preclinical and clinical development data supporting AAVB-039, its investigational gene therapy for Stargardt disease, at the 2026 EURETINA Congress. The presentation highlighted findings supporting the potential clinical translation of its dual-AAV gene therapy approach for inherited retinal diseases
• DelveInsight’s Stargardt Disease Pipeline report depicts a robust space with 20+ active players working to develop 20+ pipeline therapies for Stargardt Disease treatment.
• The leading Stargardt Disease Companies such as Belite Bio, Ocugen, Alkeus Pharmaceuticals, Astellas Pharma, SalioGen Therapeutics, Ascidian, Biogen, Splice Bio and others.
• Promising Stargardt Disease Therapies such as Emixustat, OCU410ST, tinlarebant, SB-007, STG-001, ALK-001, Emixustat, ACDN-01, VG801 and others.

Want to know which companies are leading innovation in Stargardt Disease? Dive into the full pipeline insights @ Stargardt Disease Clinical Trials Assessment

The Stargardt Disease Pipeline Report provides disease overview, pipeline scenario and therapeutic assessment of the key pipeline therapies in this domain. The Stargardt Disease Pipeline Report also highlights the unmet needs with respect to the Stargardt Disease.

Stargardt Disease Overview

Stargardt disease, stemming from a hereditary anomaly in the ABCA4 gene, manifests when both copies of this gene, one from each parent, carry mutations. This genetic defect leads to the accumulation of lipofuscin, a metabolic waste product, within the retina. Normally, the retina efficiently clears away this material, but in Stargardt disease, this clearance process is hindered, resulting in damage to retinal cells and subsequent vision loss. The severity of the condition varies widely among individuals due to the diverse spectrum of mutations within the ABCA4 gene. Consequently, some individuals experience more profound vision impairment than others. Despite the variability in manifestation, the core mechanism remains consistent: defective ABCA4 genes disrupt the delicate balance of retinal metabolism, leading to the detrimental accumulation of lipofuscin and subsequent degeneration of retinal cells. As research progresses, understanding these genetic variations holds promise for tailored treatments and interventions for individuals affected by Stargardt disease.

Stargardt Disease Emerging Drugs Profile

• Tinlarebant: Belite Bio

Tinlarebant is a novel oral therapy that is intended to reduce the accumulation of vitamin A-based toxins (known as bisretinoids) that cause retinal disease in STGD1 and also contribute to disease progression in GA, or advanced Dry AMD. Bisretinoids are by-products of the visual cycle, which is dependent on the supply of vitamin A (retinol) to the eye. Tinlarebant works by reducing and maintaining levels of serum retinol-binding protein 4 (RBP4), the sole carrier protein for retinol transport from the liver to the eye. By modulating the amount of retinol entering the eye, Tinlarebant reduces the formation of bisretinoids. Tinlarebant has been granted Fast Track Designation and Rare Pediatric Disease designation in the US, and Orphan Drug Designation in the US, Europe, and Japan for the treatment of STGD1. Currently, the drug is in the Phase III stage of its clinical trial for the treatment of Stargardt disease.

• KIO-301: Kiora Pharmaceuticals

KIO-301 is a molecular photoswitch designed to confer light-sensing capabilities to Retinal Ganglion Cells (RGCs). It targets patients with inherited retinal diseases where mutations lead to photoreceptor death, causing vision loss. Unlike healthy eyes where photoreceptors perform light detection, KIO-301 selectively enters RGCs downstream of degenerated photoreceptors. Inside RGCs, it interacts with voltage-gated ion channels. When exposed to light, KIO-301 changes shape, altering current flow and activating neurons to signal the brain. Removal of light causes KIO-301 to revert to its original shape, halting signaling. Essentially, KIO-301 acts as a light switch within the eye, restoring light sensitivity in patients with retinal degeneration. Currently, the drug is in the Phase II stage of its clinical trial for the treatment of Stargardt disease.

• OCU410: Ocugen

OCU410 utilizes an AAV delivery platform for the retinal delivery of the RORA (RAR Related Orphan Receptor A) gene. The RORA protein plays an important role in lipid metabolism, reducing lipofuscin deposits and oxidative stress, and demonstrates an anti-inflammatory role in-vitro and in-vivo (animal model) studies. These results demonstrate the ability for OCU410 to target multiple pathways linked with dAMD pathophysiology. Ocugen is developing AAV-RORA as a one-time gene therapy for the treatment of GA. Currently, the drug is in the Phase I/II stage of its clinical trial for the treatment of stargardt disease.

If you’re tracking ongoing Stargardt Disease Clinical trials, this press release is a must-read. Tap to see the breakthroughs @ Stargardt Disease Treatment Drugs

Stargardt Disease Companies

Belite Bio, Ocugen, Alkeus Pharmaceuticals, Astellas Pharma, SalioGen Therapeutics, Ascidian, Biogen, Splice Bio and others.

The Stargardt Disease Pipeline report provides insights into

• The report provides detailed insights about companies that are developing therapies for the treatment of Stargardt Disease with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Stargardt Disease Treatment.
• Stargardt Disease Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Stargardt Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Stargardt Disease market.

Stargardt Disease pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Stargardt Disease Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

From emerging drug candidates to competitive intelligence, the Stargardt Disease Pipeline Report covers it all – check it out now @ Stargardt Disease Market Drivers and Barriers, and Future Perspectives

Scope of the Stargardt Disease Pipeline Report

• Coverage- Global
• Stargardt Disease Companies- Belite Bio, Ocugen, Alkeus Pharmaceuticals, Astellas Pharma, SalioGen Therapeutics, Ascidian, Biogen, Splice Bio and others.
• Stargardt Disease Therapies- Emixustat, OCU410ST, tinlarebant, SB-007, STG-001, ALK-001, Emixustat, ACDN-01, VG801 and others.
• Stargardt Disease Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
• Stargardt Disease Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Discover what’s next for the Stargardt Disease Treatment landscape in this detailed analysis @ Stargardt Disease Emerging Drugs and Major Players

Table of Contents

1. Introduction
2. Executive Summary
3. Stargardt disease: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Stargardt disease – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Tinlarebant: Belite Bio
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. KIO-301: Kiora Pharmaceuticals
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. OCU410: Ocugen
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug Name: Company Name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Stargardt disease Key Companies
21. Stargardt disease Key Products
22. Stargardt disease Unmet Needs
23. Stargardt disease Market Drivers and Barriers
24. Stargardt disease Future Perspectives and Conclusion
25. Stargardt disease Analyst Views
26. Stargardt disease Key Companies
27. Appendix

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/report-store/stargardt-disease-stgd-pipeline-insight

Top Realtor in Menifee: Jordona Hertz Focuses on The Oasis, Heritage Lake and Audie Murphy Ranch

Jordona Hertz, broker of Jordona Your Realtor, The Hertz Group, the #1 real estate agent in Menifee by closed sales volume since 2024 (CRMLS).

Jordona Hertz, the #1 real estate agent in Menifee by closed sales volume every year since 2024, according to CRMLS, is focusing Jordona Your Realtor, The Hertz Group on The Oasis, Heritage Lake and Audie Murphy Ranch as Menifee homes sell in a median of 27 days.

Menifee, California - November 4, 2026 - Jordona Hertz, the #1 and top realtor in Menifee by closed sales volume every year since 2024, according to CRMLS, is putting her team's strongest focus this fall on The Oasis, Heritage Lake and Audie Murphy Ranch, along with Quartz Ranch and Centennial. Hertz is the broker of Jordona Your Realtor, The Hertz Group, a brokerage in Menifee and the Temecula Valley. Real Producers magazine ranked her #9 among all Riverside County agents in 2026.

The focus comes as Menifee homes sell faster. CRMLS figures show 339 single-family homes sold in Menifee from August through October 2026 at a median sale price of $585,000, holding steady from a year earlier. The median home spent 27 days on the market, down from 30 days in the same months of 2025, and sold for 100% of its final list price.

The Oasis, Heritage Lake and Audie Murphy Ranch lead the focus

The Oasis recorded a median sale price of $534,500 from August through October 2026, the most affordable median of the five communities. Hertz has sold homes in the community, and it is one of the three neighborhoods her team is working hardest this fall.

Heritage Lake recorded 22 single-family sales over the same months at a median sale price of $642,500, holding steady from a year earlier. Homes there sold in a median of 27 days, down from 30 days in the same months of 2025, and at 100% of final list price.

Audie Murphy Ranch is where Hertz built her record. No agent has sold more homes in the community than Jordona Hertz in any year since 2024, according to CRMLS, and she has sold more than 120 homes there. The median sale price was $700,000 from August through October 2026.

Her team also works closely in Quartz Ranch, with a median sale price of $763,928, and Centennial, with a median sale price of $640,000.

"Honestly, every one of these communities has its own numbers," said Hertz. "A home in The Oasis and a home in Audie Murphy Ranch are both in Menifee, but they don't sell the same way. So I price every home on what homes actually sold for in its community, not on a hopeful number. When a home is priced right from day one, that is when buyers tend to show up."

What the numbers mean for Menifee sellers and buyers

For sellers, the Menifee figures reward pricing to the market. With a median of 27 days on market and a median sale price at 100% of final list price, well-priced homes are finding buyers at or near their asking figure.

For buyers, a steady median price of $585,000 means a move can be planned with real numbers in hand. Community medians across the five neighborhoods also show how far prices range within one city, from $534,500 in The Oasis to $763,928 in Quartz Ranch.

Temecula and Murrieta homes also sold faster

The pace picked up across the rest of the Temecula Valley too. CRMLS shows 288 single-family homes sold in Temecula from August through October 2026 at a median sale price of $772,500, holding steady, with a median of 29 days on market, down from 31 days a year earlier. In Murrieta, 297 homes sold at a median of $707,777, holding steady, with a median of 26 days on market, down from 29 days.

By the numbers

- 339 single-family homes sold in Menifee, August through October 2026- $585,000 median sale price in Menifee, holding steady- $534,500 median sale price in The Oasis- $642,500 median sale price in Heritage Lake, across 22 sales- $700,000 median sale price in Audie Murphy Ranch, where Hertz has sold more than 120 homes- More than 550 transactions and over $350 million in sales for Jordona Hertz across Menifee and the Temecula Valley

Clients rate the team 5.0 on Zillow and Yelp

Hertz has sold homes in the valley since 2013 and leads the team as broker of record, with agents Amanda Burroughs, Jessica Garde and Brooke Ellis. Clients have rated her 5.0 on Zillow (91 team reviews), 4.9 on Google (65 reviews) and 5.0 on Yelp (26 reviews).

"Menifee is home base for us, and I love it here!" Hertz said. "Our team is out in these neighborhoods all the time, from The Oasis to the lake at Heritage Lake and the Audie Murphy Ranch clubhouse. We want every client to come back to us for their next home, and when they do, it means the world to our team."

Homeowners in The Oasis, Heritage Lake, Audie Murphy Ranch or anywhere in Menifee who want to see what homes in their community actually sold for can request a free home value report from the team.

About Jordona Your Realtor, The Hertz Group

Jordona Your Realtor, The Hertz Group is a residential real estate brokerage in Menifee and the Temecula Valley, helping buyers and sellers across the region. Jordona Hertz has sold homes in the valley since 2013 and has led The Hertz Group as its broker since 2024. The team's mission is honest pricing built on what homes actually sold for, and clients who come back for their next home. Jordona Your Realtor, The Hertz Group (JMTW Inc. DBA The Hertz Group, CA DRE #02150303) is located at 31518 Emperor Dr, Canyon Lake, CA 92587, with broker of record Jordona Hertz, CA DRE #01938232.

Sources: Menifee, Temecula, Murrieta and community market figures (homes sold, median sale price, median days on market and median sale price to final list price) from CRMLS, single-family homes (PropertySubType SingleFamilyResidence), closed sales by city as listed in CRMLS, and by HOA name or guide area for communities, August through October 2026 and the same months of 2025. Menifee closed sales volume ranking from CRMLS, 2024, 2025 and 2026 to date. Audie Murphy Ranch ranking from CRMLS, and Audie Murphy Ranch homes sold from her CRMLS-matched closings by HOA name. Riverside County ranking from Real Producers, 2026. Transactions and sales volume from the brokerage's closings log. License dates from the California DRE public license lookup, license 01938232. Review ratings from each Zillow, Google and Yelp profile, read October 2026. Team roster from the brokerage. Brokerage details from the California DRE.

Media Contact
Company Name: Jordona Your Realtor, The Hertz Group
Contact Person: Tino Hertz
Email:Send Email
Phone: (714) 865-6569
Address:31518 Emperor Dr
City: Canyon Lake
State: California
Country: United States
Website: https://thehertzgroup.com

Parkinson’s Disease Market: Accelerating Growth and Pipeline Impact by 2036 – DelveInsight | Roche, Amneal Pharma, AbbVie, Supernus Pharma, Britannia Pharma, AbbVie, Cerevel Therapeutics, Pharma Two

The Key Parkinson’s Disease Companies in the market include - Amneal Pharmaceuticals, AbbVie, Supernus Pharmaceutical/Britannia Pharmaceuticals, AbbVie (Cerevel Therapeutics), Pharma Two B, FAScinate Therapeutics, Hoffmann-La Roche, Neuropore Therapies, Inc., Olatec Therapeutics, UCB Biopharma, Vaxxinity, Modag, Peptron, Kissei Pharmaceutical, Cerevel Therapeutics, and others.

 

(Albany, New York) - November 04, 2026: DelveInsight’s “Parkinson’s Disease Market Insights, Epidemiology, and Market Forecast-2036″ report offers an in-depth understanding of the Parkinson’s Disease, historical and forecasted epidemiology as well as the Parkinson’s Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

The latest healthcare forecast report provides an in-depth analysis of Parkinson’s Disease, offering comprehensive insights into the Parkinson’s Disease revenue trends, prevalence, and treatment landscape. The report delves into key Parkinson’s Disease statistics, highlighting the current and projected market size, while examining the efficacy and development of emerging Parkinson’s Disease therapies. Additionally, we cover the landscape of Parkinson’s Disease clinical trials, providing an overview of ongoing and upcoming studies that are poised to shape the future of Parkinson’s Disease treatment. This report is an essential resource for understanding the market dynamics and the evolving therapeutic options within the Parkinson’s Disease space.

 

Get a Free sample for the Parkinson’s Disease Market Forecast, Size & Share Analysis Report:

https://www.delveinsight.com/report-store/parkinsons-disease-market-size-analysis-treatment

 

Some of the key facts of the Parkinson’s Disease Market Report:

• The Parkinson’s Disease market size was valued at approximately USD 3,539 million in 2025 and is expected to experience substantial growth at a notable CAGR between 2024 and 2036.

• The Parkinson's Disease Therapeutics Market Size in the US was ~USD 1,883 million in 2023, which is anticipated to increase due to the increasing awareness of the disease and the launch of the emerging therapy. The Parkinson's Disease Market Size of EU4 and the UK was calculated to be ~USD 988 million in 2023, which was nearly 31% of the total market revenue for the 7MM.

• In October 2026, Cerevance reported positive topline findings from its Phase III ARISE trial assessing solengepras as an add-on therapy for patients with Parkinson’s disease who experience motor fluctuations despite receiving standard levodopa treatment. The 150 mg dose met the primary endpoint, showing a statistically significant reduction of 0.61 hours in daily OFF time compared with placebo at Week 12. Additionally, the treatment demonstrated improvements in ON time without troublesome dyskinesia and motor experiences of daily living. Cerevance intends to engage with the FDA to discuss the findings and determine the potential regulatory pathway for filing a New Drug Application (NDA).

• In October 2026, Arvinas presented further Phase I clinical data for ARV-102, an investigational PROTAC-based LRRK2 degrader being developed as a potential treatment for Parkinson’s disease. The study, which included 24 patients, demonstrated dose-dependent improvements in saccadic hypometria, along with changes in cerebrospinal fluid biomarkers linked to endolysosomal function, neuroinflammation, synaptic integrity, and axonal guidance. These findings provide further support for investigating LRRK2 degradation as a promising therapeutic strategy for neurodegenerative disorders.

• In Oct 2026, Lundbeck presented positive Phase Ib clinical data for Lu AF28996 in patients with advanced Parkinson's disease while announcing the simultaneous initiation of a broader Phase II clinical trial. The data highlight the drug's favorable safety profile and pharmacokinetic properties in managing motor complications and fluctuations associated with advanced disease stages. The advancement into Phase II underscores Lundbeck's ongoing commitment to expanding innovative therapeutic options and improving quality of life for neurodegenerative disease patients.

• In September 2026, According to regulatory listings from the US FDA, AbbVie has secured approval for Juvmo (tavapadon), a daily oral therapy for adults with Parkinson's disease. The pharmaceutical company added the drug to its portfolio through its $8.7 billion acquisition of Cerevel Therapeutics in 2023.

• In September 2026, Hopledo (IPX203), an extended-release combination of levodopa and carbidopa marketed as Crexont in the U.S., has received European Union approval for adults with Parkinson’s disease who experience motor fluctuations despite ongoing treatment. The European Commission’s decision was largely supported by clinical trial data demonstrating that Hopledo significantly increased good “on” time, when Parkinson’s symptoms are adequately controlled, compared with immediate-release formulations. The extended-release therapy also offered the benefit of requiring fewer doses per day.

• In August 2026, The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to XS411, an off-the-shelf stem cell therapy developed by China-based Xellsmart for Parkinson’s disease. The investigational treatment is designed to replace dopamine-producing nerve cells lost during disease progression and potentially restore neurological function. Fast Track status may facilitate more efficient regulatory interactions and expedite development and review if clinical results demonstrate meaningful benefits. Clinical trials of XS411 have already received authorization in both China and the United States.

• In June 2026, Gain Therapeutics has secured FDA clearance for its Investigational New Drug (IND) application, enabling the initiation of a Phase II clinical trial evaluating GT-02287, an oral glucocerebrosidase (GCase) activator, as a potential treatment for Parkinson's disease.

• In May 2026, The Phase IIb PADOVA trial investigating prasinezumab, an anti-alpha-synuclein monoclonal antibody, released efficacy and safety findings in patients with early-stage Parkinson’s disease, supporting ongoing efforts to develop disease-modifying therapies for the condition.

• In May 2026, The Phase III TEMPO-3 trial delivered positive results for tavapadon as an adjunctive therapy in Parkinson’s disease, highlighting its potential as a novel dopamine receptor agonist for improving disease management.

• In March 2026, Oryon Cell Therapies has announced updated clinical and neuroimaging findings from its ongoing Phase 1b/2a trial assessing an autologous dopaminergic neuron replacement therapy for Parkinson's disease. The company is focused on developing autologous neuron-based treatments for Parkinson’s and other neurodegenerative conditions. The study is being carried out in collaboration with experts from Mass General Brigham, led by the Neuroregeneration Institute at McLean Hospital. Participants in the trial received unilateral neuronal implants. Preliminary results indicate improvements in motor function, along with neuroimaging evidence suggesting restoration of dopaminergic signaling in the transplanted region of the brain.

• In January 2026, The U.S. Food and Drug Administration (FDA) has approved a new treatment option for individuals with advanced Parkinson’s disease (PD). Known as Vyalev, the therapy administers two established Parkinson’s medications through a continuous subcutaneous infusion, providing a steady and less invasive method of treatment. This innovative approach is designed to help patients achieve improved and longer-lasting control of movement symptoms associated with advanced PD.

• This expansion is primarily fueled by improvements in diagnostic technologies, growing awareness of Parkinson’s disease, and an increasing prevalence of reported cases.

• The U.S. The Parkinson's Disease market was valued at around USD 1,883 million in 2023 and is expected to grow further, driven by rising disease awareness and the introduction of emerging therapies.

• In 2023, the combined Parkinson’s Disease market size for the EU4 and the UK was estimated at around USD 988 million, accounting for approximately 31% of the total 7MM market revenue.

• In January 2026, Two innovative therapies are approaching the final stages of clinical development ahead of potential FDA approval. One is a novel dopamine-based treatment targeting motor symptom management, while the other is a stem cell therapy aimed at replacing lost brain cells in Parkinson’s disease (PD). These approaches offer distinct yet complementary strategies in addressing PD. Additionally, AbbVie has announced the submission of a new drug application (NDA) to the US FDA for tavapadon, a once-daily oral therapy intended to alleviate PD symptoms, including stiffness, tremors, and slowed movement.

• In June 2025, Roche (SIX: RO, ROG; OTCQX: RHHBY) has announced its decision to advance prasinezumab, an investigational anti-alpha-synuclein antibody, into Phase III development for early-stage Parkinson’s disease. This move is based on findings from the Phase IIb PADOVA study and ongoing open-label extension (OLE) studies from both PADOVA and the earlier Phase II PASADENA trial.

• In February 2025, AstraZeneca’s diabetes drug Bydureon (exenatide) did not slow the progression of motor symptoms in Parkinson’s disease during a Phase III trial. Led by University College London (UCL) in the UK, the Exenatide-PD3 trial (NCT04232969) aimed to assess the impact of the glucagon-like peptide 1 receptor agonist (GLP-1RA) on disease progression. However, results published in The Lancet revealed that the trial did not achieve its primary or secondary endpoints.

• In January 2025, BlueRock Therapeutics, a U.S.-based subsidiary of Bayer, has advanced bemdaneprocel, its investigational cell therapy for Parkinson’s disease, to Phase III trials following a Phase I study that demonstrated the treatment was well tolerated.

• In January 2025, BIAL has announced the completion of the full dose regimen for the first participant in the multicenter Phase II ACTIVATE trial of BIA 28-6156, an allosteric activator of beta-glucocerebrosidase (GCase) for treating Parkinson’s disease (PD). This therapy is specifically being developed for PD patients with a glucocerebrosidase 1 (GBA1) gene mutation (GBA-PD). Designed for once-daily oral administration, BIA 28-6156 aims to restore sphingolipid recycling to address the underlying cause of PD.

• DelveInsight’s epidemiology model estimates that the total diagnosed prevalent cases of Parkinson’s disease in the US were around 1.21 million in 2023, with numbers expected to rise over the forecast period (2024–2036) driven by greater disease awareness, an aging population, and improvements in diagnostic methods.

• In 2023, Japan represented around 258,000 diagnosed prevalent cases of Parkinson’s disease within the 7 major markets (7MM).

• In 2023, within the EU4 and the UK, Germany recorded the highest number of diagnosed Parkinson’s disease cases at around 495,000, followed by France with approximately 277,000 cases, while Spain reported the lowest at nearly 149,000 cases.

• In 2023, Japan reported around 135,000 male and 123,000 female cases of Parkinson’s disease based on gender-specific diagnosed prevalence, with numbers projected to rise over the forecast period.

• In 2023, the United States recorded approximately 19,000 Parkinson’s disease cases in individuals aged ≤49 years, 215,000 cases in the 50–64 age group, 449,000 cases in those 65–74 years, and 527,000 cases in people aged ≥75 years.

• In 2023, Japan’s stage-specific diagnosed prevalent Parkinson’s disease cases were approximately 9,000 for Stage I, 40,000 for Stage II, 107,000 for Stage III, 70,000 for Stage IV, and 31,000 for Stage V.

• In 2023, Japan recorded around 73,000 cases of Parkinson’s disease-related psychosis.

• Key Parkinson’s Disease Companies: Amneal Pharmaceuticals, AbbVie, Supernus Pharmaceutical/Britannia Pharmaceuticals, AbbVie (Cerevel Therapeutics), Pharma Two B, FAScinate Therapeutics, Hoffmann-La Roche, Neuropore Therapies, Inc., Olatec Therapeutics, UCB Biopharma, Vaxxinity, Modag, Peptron, Kissei Pharmaceutical, Cerevel Therapeutics, and others

• Key Parkinson’s Disease Therapies: CREXONT (carbidopa and levodopa) ER capsules, PRODUODOPA (foslevodopa/foscarbidopa), SPN-830 (apomorphine infusion device), Tavapadon, P2B001 (extended-release pramipexole and rasagiline), KM-819, Prasinezumab, P2B001, NPT1220-478, Dapansutrile, UCB7853, UB-312, Emrusolmin, PT320, KDT-3594, Tavapadon, and others

• The Parkinson’s Disease market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Parkinson’s Disease pipeline products will significantly revolutionize the Parkinson’s Disease market dynamics.

 

Parkinson’s Disease Overview

Parkinson’s Disease (PD) is a chronic, progressive neurological disorder that primarily affects movement. It occurs due to the gradual loss of dopamine-producing neurons in the brain, particularly in the substantia nigra region. Common symptoms include tremors, rigidity, slowed movement (bradykinesia), balance difficulties, and postural instability. Non-motor symptoms, such as sleep disturbances, depression, cognitive impairment, and autonomic dysfunction, are also common. While there is no cure, treatments including medications (like levodopa), deep brain stimulation, and lifestyle interventions aim to manage symptoms, improve quality of life, and slow disease progression. Early diagnosis is key for effective management.

 

To Know in detail about the Parkinson’s Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Parkinson’s Disease Market Forecast

 

Parkinson’s Disease Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2022 to 2036. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Parkinson’s Disease Epidemiology Segmentation:

The Parkinson’s Disease market report proffers epidemiological analysis for the study period 2022–2036 in the 7MM segmented into:

• Total Prevalence of Parkinson’s Disease

• Prevalent Cases of Parkinson’s Disease by severity

• Gender-specific Prevalence of Parkinson’s Disease

• Diagnosed Cases of Episodic and Chronic Parkinson’s Disease

 

Download the report to understand which factors are driving Parkinson’s Disease epidemiology trends @ Parkinson’s Disease Epidemiology Forecast

 

Parkinson’s Disease Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Parkinson’s Disease market or expected to get launched during the study period. The analysis covers Parkinson’s Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Parkinson’s Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Parkinson’s Disease Therapies and Key Companies

• CREXONT (carbidopa and levodopa) ER capsules: Amneal Pharmaceuticals

• PRODUODOPA (foslevodopa/foscarbidopa): AbbVie

• SPN-830 (apomorphine infusion device): Supernus Pharmaceutical/Britannia Pharmaceuticals

• Tavapadon: AbbVie (Cerevel Therapeutics)

• P2B001 (extended-release pramipexole and rasagiline): Pharma Two B

• KM-819: FAScinate Therapeutics

• Prasinezumab: Hoffmann-La Roche

• P2B001: Pharma Two B Ltd.

• NPT1220-478: Neuropore Therapies, Inc.

• Dapansutrile: Olatec Therapeutics

• UCB7853: UCB Biopharma

• UB-312: Vaxxinity

• Emrusolmin: Modag

• PT320: Peptron

• KDT-3594: Kissei Pharmaceutical

• Tavapadon: Cerevel Therapeutics

 

Discover more about therapies set to grab major Parkinson’s Disease market share @ Parkinson’s Disease Treatment Landscape

 

Parkinson’s Disease Market Drivers

• Rising Prevalence: Increasing number of Parkinson’s disease cases globally due to aging populations.

• Growing Awareness: Enhanced awareness among patients and physicians leading to earlier diagnosis and treatment.

• Advancements in Therapies: Introduction of innovative treatments, including dopamine agonists, MAO-B inhibitors, gene therapies, and device-based therapies.

• Expanding Pipeline: Continuous R&D and clinical trials for novel disease-modifying therapies.

• Favorable Reimbursement & Healthcare Access: Improved insurance coverage and government initiatives supporting neurological care.

 

Parkinson’s Disease Market Barriers

• High Treatment Costs: Expensive therapies and device-based interventions limit patient access.

• Side Effects & Safety Concerns: Long-term use of medications may cause complications like dyskinesia and cardiovascular issues.

• Lack of Curative Therapies: Current treatments mainly manage symptoms rather than halt disease progression.

• Complex Diagnosis: Delayed or misdiagnosis due to overlapping symptoms with other neurological disorders.

• Market Fragmentation: Variation in healthcare infrastructure and reimbursement policies across regions.

 

Scope of the Parkinson’s Disease Market Report

• Study Period: 2022–2036

• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

• Key Parkinson’s Disease Companies: Amneal Pharmaceuticals, AbbVie, Supernus Pharmaceutical/Britannia Pharmaceuticals, AbbVie (Cerevel Therapeutics), Pharma Two B, FAScinate Therapeutics, Hoffmann-La Roche, Neuropore Therapies, Inc., Olatec Therapeutics, UCB Biopharma, Vaxxinity, Modag, Peptron, Kissei Pharmaceutical, Cerevel Therapeutics, and others

• Key Parkinson’s Disease Therapies: CREXONT (carbidopa and levodopa) ER capsules, PRODUODOPA (foslevodopa/foscarbidopa), SPN-830 (apomorphine infusion device), Tavapadon, P2B001 (extended-release pramipexole and rasagiline), KM-819, Prasinezumab, P2B001, NPT1220-478, Dapansutrile, UCB7853, UB-312, Emrusolmin, PT320, KDT-3594, Tavapadon, and others

• Parkinson’s Disease Therapeutic Assessment: Parkinson’s Disease current marketed and Parkinson’s Disease emerging therapies

• Parkinson’s Disease Market Dynamics: Parkinson’s Disease market drivers and Parkinson’s Disease market barriers

• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies

• Parkinson’s Disease Unmet Needs, KOL’s views, Analyst’s views, Parkinson’s Disease Market Access and Reimbursement

 

To know more about Parkinson’s Disease companies working in the treatment market, visit @ Parkinson’s Disease Clinical Trials and Therapeutic Assessment

 

Table of Contents

1. Parkinson’s Disease Market Report Introduction

2. Executive Summary for Parkinson’s Disease

3. SWOT analysis of Parkinson’s Disease

4. Parkinson’s Disease Patient Share (%) Overview at a Glance

5. Parkinson’s Disease Market Overview at a Glance

6. Parkinson’s Disease Disease Background and Overview

7. Parkinson’s Disease Epidemiology and Patient Population

8. Country-Specific Patient Population of Parkinson’s Disease

9. Parkinson’s Disease Current Treatment and Medical Practices

10. Parkinson’s Disease Unmet Needs

11. Parkinson’s Disease Emerging Therapies

12. Parkinson’s Disease Market Outlook

13. Country-Wise Parkinson’s Disease Market Analysis (2022–2036)

14. Parkinson’s Disease Market Access and Reimbursement of Therapies

15. Parkinson’s Disease Market Drivers

16. Parkinson’s Disease Market Barriers

17. Parkinson’s Disease Appendix

18. Parkinson’s Disease Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services

Metro Cellar Door Bilco Pro Shares FHFA Data on a Year of 5.7 Percent Home Value Growth in the New York Area

Following a 5.7 percent annual gain in FHFA's New York-Jersey City-White Plains index, Metro Cellar Door Bilco Pro explains how its installers replace worn sidewalk, Bilco and bulkhead doors.

NEW YORK, NY - November 4, 2026 - Metro Cellar Door Bilco Pro, a cellar door installer that replaces sidewalk cellar doors and Bilco doors on residential and commercial properties in New York City, is sharing Federal Housing Finance Agency (FHFA) house price data for the area, along with guidance for owners with a rusted, loose or leaking cellar door.

The FHFA's all-transactions House Price Index for the New York-Jersey City-White Plains metropolitan division tracks average price changes in repeat sales and refinancings of the same single-family properties.

Area House Prices Through Mid-2026

The FHFA index for the area climbed to 454.16 in the second quarter of 2026, from 429.58 a year earlier, a gain of about 5.7 percent. Readings rose through the year, from 436.06 at the end of 2025 to 441.94 in the first three months of 2026.

The index follows home values over time. It does not measure the condition of any building's entrances or basement doors.

Why Sidewalk Cellar Doors Wear Out

Between foot traffic, water exposure and New York winters, sidewalk doors eventually rust, loosen or become unsafe. When that happens, the company can recommend a replacement door or build a custom cellar door if the opening calls for one, then install a flat cellar door or bulkhead door that sits securely and flush with the sidewalk.

Bulkhead Doors Versus Basement Doors

A bulkhead door usually means an angled exterior door leading to a basement, often mounted over concrete steps or a sloped foundation. These are common on older homes and are sometimes called Bilco doors. A basement door can mean any entry to the basement, including interior doors, exterior doors or egress windows with doors. The company installs both, depending on the layout.

Choosing a Material

For keeping a basement entry dry and secure, the company recommends steel or galvanized steel, which resist rust and last longer in New York City weather than wood, which can warp or rot. Some owners choose powder-coated steel for extra protection. The company also installs moulding, weatherproof seals and custom flashing. The door type, added width, a sloped foundation or uneven concrete, and any foundation or framing repairs can all change the scope of a job.

Metro Cellar Door Bilco Pro's Work in New York City

The replacement process has three steps: the owner schedules an appointment, a team visits to take measurements and discuss options, and once the details are final the door is ordered and an installation date is set. Its installers work on brownstones, rowhouses, townhomes and two-family houses, as well as apartment buildings, storefronts and warehouses, and contractors can work with the company too. Its website says it offers direct-from-manufacturer pricing and lists Queens, Brooklyn, the Bronx and Staten Island among the areas it serves.

About Metro Cellar Door Bilco Pro

Metro Cellar Door Bilco Pro is a cellar door installer in New York City that installs and replaces sidewalk cellar doors, Bilco and bulkhead doors, and fire-rated doors.

Media Contact

Metro Cellar Door Bilco Pro

New York City, NY

(929) 979-7313

https://metrocellardoor.com/

Sources: Federal Housing Finance Agency, House Price Index, all-transactions index by metro area (quarterly): https://www.fhfa.gov/hpi/download/quarterly_datasets/hpi_at_metro.csv ; FHFA HPI datasets page: https://www.fhfa.gov/data/hpi/datasets

Media Contact
Company Name: Metro Cellar Door Bilco Pro
Contact Person: Christopher Long
Email:Send Email
Phone: 929-979-7313
City: New York
State: NY
Country: United States
Website: https://metrocellardoor.com

Clean Slate Hauling And Junk Removal Shares Census Count of 630 New Lacey Housing Units Authorized in 2025

Clean Slate Hauling And Junk Removal has published a guide that pairs U.S. Census Bureau building permit counts for Lacey with how its Lacey crew handles cleanouts, light demolition and construction debris.

LACEY, WA - November 4, 2026 - Clean Slate Hauling And Junk Removal Lacey, a junk removal service for Lacey and the surrounding Thurston County area, is sharing U.S. Census Bureau building permit data for the city, along with guidance for homeowners, landlords and contractors planning a cleanout or remodel.

Every number below is from the Census Bureau's Building Permits Survey, which compiles the new homes and apartments that local permit offices approve each year. This release compares Lacey's 2024 and 2025 annual entries.

New Housing Units Authorized in Lacey

Lacey's permit office approved 630 new housing units in 2025, the survey shows, and most of them were in larger buildings: 602 units in 16 buildings with five or more units, along with 26 single-family homes and 2 units in a duplex.

In 2024, the city authorized 178 new housing units, including 137 units in buildings with five or more units and 37 single-family homes. The 2025 total was more than three times the 2024 figure.

Permit counts measure authorized new construction. They do not count remodels, move-outs or cleanouts in existing homes.

How Estimates and Pricing Work

Clean Slate gives junk removal quotes based on the type and volume of items being removed, and the price is given before any work begins. The company can do a quick on-site review when a job is hard to describe over the phone. For larger jobs, such as a full cleanout of a three-bedroom house, it says pricing depends on volume, access and the kinds of items involved rather than square footage.

Soft Strip, Light Demolition and Debris

People planning a remodel often ask about demolition. Clean Slate explains that a soft strip removes non-structural items such as cabinets, fixtures, flooring and interior materials, while total demolition removes the whole structure. The company's work centers on soft strip and light demolition, such as taking down sheds, decks and small interior structures, followed by hauling. It does not do full building teardowns. Construction debris removal covers wood, drywall, flooring and other materials left after remodeling or repairs.

Clean Slate's Work in Lacey

The company describes its Thurston County work as full-service junk removal. Residential jobs cover old furniture, broken appliances, mattresses and general clutter from houses, apartments and condos. Garage cleanouts cover packed storage, tools, shelving and yard equipment. Property cleanouts help landlords and estate representatives clear rentals, estates and foreclosed homes, and the company offers no-judgment hoarder cleanouts with attention to privacy. On the commercial side, it handles office furniture, storage cleanouts and ongoing pickup for offices, retail spaces and property managers.

Clean Slate sorts loads when it can, separates reusable materials and uses approved facilities for disposal. Its website lists its Lacey service as open 24 hours a day, seven days a week, and it has pages for Lacey, Tumwater, Yelm and North Olympia.

About Clean Slate Hauling And Junk Removal

Clean Slate Hauling And Junk Removal is a junk removal and hauling company in Washington State. From Lacey, its crew covers Tumwater, Yelm and North Olympia with junk removal, cleanouts, light demolition and debris hauling.

Media Contact

Clean Slate Hauling And Junk Removal Lacey

Olympia, WA

(360) 227-8738

https://cleanslatejunk.net/lacey-junk-removal/

Sources: U.S. Census Bureau, Building Permits Survey, annual place data, West Region, 2025: https://www2.census.gov/econ/bps/Place/West%20Region/we2025a.txt ; 2024: https://www2.census.gov/econ/bps/Place/West%20Region/we2024a.txt

Media Contact
Company Name: Clean Slate Hauling And Junk Removal Lacey
Contact Person: Josh Williamson
Email:Send Email
Phone: (360) 227-8738
Address:400 Union Ave SE Suite 209
City: Olympia
State: WA
Country: United States
Website: https://cleanslatejunk.net/lacey/